Abstract Background A previous European Headache Federation (EHF) guideline
addressed the use of monoclonal antibodies targeting the calcitonin gene-related peptide …

Objective: To perform a systematic review of real-world outcomes for anti-CGRP-mAbs.
Methods: Following the PRISMA guidelines, we searched PubMed for real-world data of …

Background In individuals with migraine, attacks may increase in frequency, severity, or
both. Preventing migraine progression has emerged as a treatment goal in headache …

Background Chronic migraine can be a profoundly disabling disorder that may be treated
with preventive medications. However, uncertainty remains as to which preventive …

Chronic migraine is one of the most devastating headache disorders. The estimated
prevalence is 1.4–2.2% in the population. The factors which may predispose to the process …

Background Despite high efficacy and tolerability, not all patients with chronic migraine
benefit from anti-CGRP monoclonal antibodies. We aimed to identify the clinical predictors of …

Background This systematic review focuses on chronic migraine patients with medication
overuse headache using, respectively, topiramate, botulinum toxin type A, and human …

Introduction Chronic headache due to the overuse of medication for the treatment of
migraine attacks has a prevalence of 0.5–2.0%. This guideline provides guidance for the …

Medication overuse headache (MOH), the development or worsening of chronic headache
resulting from frequent and excessive intake of medications used for acute treatment of …

Objective This post hoc analysis in patients medically diagnosed with chronic migraine (CM)
and medication‐overuse headache (MOH) evaluated reductions in the use of acute …